Delving into the Latest Updates on MH080 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

MH080

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Plaque psoriasis

Inactive Indication-

Originator Organization

Minghui Pharmaceutical (Hangzhou) Co., Ltd.Startup

Active Organization

Minghui Pharmaceutical (Hangzhou) Co., Ltd.StartupMinghui Pharmaceutical (Shanghai) Co., Ltd.

Austarpharma, Inc.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the preliminary efficacy of MH080 cream in the treatment of patients with plaque psoriasis. Secondary objectives: 1. To evaluate the safety and tolerability of MH080 cream in patients with plaque psoriasis. 2. To evaluate the pharmacokinetic characteristics of MH080 cream in patients with plaque psoriasis.

Start Date-

Sponsor / Collaborator

Minghui Pharmaceutical (Shanghai) Co., Ltd.

[+2]

100 Clinical Results associated with MH080

Login to view more data

100 Translational Medicine associated with MH080

Login to view more data

100 Patents (Medical) associated with MH080

Login to view more data

100 Deals associated with MH080

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plaque psoriasis	Phase 2	CN	Minghui Pharmaceutical (Hangzhou) Co., Ltd.Startup	06 Apr 2023
Plaque psoriasis	Phase 2	CN	Minghui Pharmaceutical (Shanghai) Co., Ltd.	06 Apr 2023
Plaque psoriasis	Phase 2	CN	Austarpharma, Inc.	06 Apr 2023